Novo Nordisk's market valuation soared to $566 billion on March 7, beating both Tesla and Visa
The maker of weight-loss drug Wegovy also became the 12th most valuable company in global rankings
The surge for the Danish drugmaker came after positive early trial data for a new obesity drug
Novo told investors a Phase I trial of the pill version of experimental drug amycretin
showed participants lost 13.1% of their weight after 12 weeks
Wegovy showed less than half of that result in the same time period during its trials
Investors believe it all means Novo has more in its pipeline beyond Wegovy
Its shares have risen more than three-fold since June 2021, when it launched Wegovy in the U.S.
Last year, Novo became Europe's most valuable company, ahead of LVMH
Novo and Eli Lilly lead the obesity drug market, forecast by analysts to be worth $100 billion by 2030
